May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab (Avastin®) in Patients With Bilateral, Idiopathic, Acquired Parafoveolar Telangiectasis (2A)
Author Affiliations & Notes
  • C. Simader
    Ophthalmology, University of Vienna, Vienna, Austria
  • S. Michels
    Ophthalmology, University of Vienna, Vienna, Austria
  • F. Prager
    Ophthalmology, University of Vienna, Vienna, Austria
  • W. Geitzenauer
    Ophthalmology, University of Vienna, Vienna, Austria
  • M. Georgopoulos
    Ophthalmology, University of Vienna, Vienna, Austria
  • K. Polak
    Ophthalmology, University of Vienna, Vienna, Austria
  • U. Schmidt-Erfurth
    Ophthalmology, University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships C. Simader, None; S. Michels, None; F. Prager, None; W. Geitzenauer, None; M. Georgopoulos, None; K. Polak, None; U. Schmidt-Erfurth, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4146. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Simader, S. Michels, F. Prager, W. Geitzenauer, M. Georgopoulos, K. Polak, U. Schmidt-Erfurth; Intravitreal Bevacizumab (Avastin®) in Patients With Bilateral, Idiopathic, Acquired Parafoveolar Telangiectasis (2A). Invest. Ophthalmol. Vis. Sci. 2007;48(13):4146.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate intravitreal bevacizumab in patients with bilateral, idiopathic, acquired parafoveolar telangiectasis (2A)

Methods:: In a retrospective study the effect and safety of intravitreal bevacizumab (Avastin®) in 10 eyes of 8 patients with bilateral parafoveolar telangiectasis (group 2A) stages 3 to 5 were evaluated. Retreatment was based on fluorescein angiography (FA) and clinical appearance. Patients were monitored using visual acuity (VA), fluorescein angiography (FA), biomicroscopy and optical coherence tomography (OCT).

Results:: No safety concerns were apparent in up to 13 months (mean 5.5 months) follow-up. All eyes showed a reduction or resolution of leakage in FA at 1 month follow-up associated with an improvement in visual acuity. Mean visual acuity improved from 20/63 at baseline to 20/40 at month 3. Central retinal thickness (CRT) as measured by OCT was moderately reduced within the first 3 months from 247µm to 192µm. At the last follow-up visit (mean 5.5 months) VA remained stable at 20/40. The mean number of treatments required was 1.9.

Conclusions:: Intravitreal bevacizumab appears a promising treatment option for bilateral, idiopathic, acquired parafoveolar telangiectasis (2A) in short term follow-up.

Keywords: macula/fovea • edema • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×